Gold+
What is the roles of Lonsurf (TAS-102) for the treatment of CRC/GC patients?
| Address | 343, Sapyeong-daero, Seocho-gu, Seoul, 06543, Korea | ||
|---|---|---|---|
| Telephone | +82-2-549-7451 | Fax | +82-2-546-5054 |
| Website | https://www.jeilpharm.co.kr | webmaster@jeilpharm.co.kr | |
Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. We challenge constantly in order to generate innovative and integrated values for the happiness and health of people worldwide. Jeil Pharm has strong sales and marketing in the Korean market and also have close cooperation with foreign partners, and capable of accommodating diverse partnership models.
Lonsurf is a combination of Trifluridine (FTD) and Tipiracil hydrochloride (TPI). FTD is inserted into DNA to show anti-tumor effect, and TPI suppresses the breakdown of FTD to elongate the duration of its action. Lonsurf is orally administered to adults at the initial dose (usually about 35 mg/m2/time of FTD per dose) twice a day for 5 consecutive days according to the body surface area, and then take a break for 2 days. This is repeated twice and the drug is taken off for 14 days. Do this as 1 cycle and repeat administration. Lonsurf is indicated for metastatic colorectal cancer and metastatic gastric cancer as palliative therapy.
TS-1 is a 5-FU anticancer drug which consists of three components, tegafur/gimeracil/oteracil potassium. TS-1 has a wide range of indications: 1) Postoperative adjuvant therapy for gastric cancer 2) Palliative therapy for advanced/metastatic gastric cancer, head and neck cancer, pancreatic cancer, and NSCLC.
